Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

Oncology Drugs Approved For
Lung Cancer by US FDA

IPN, New Delhi can facilitate patient to import of "Oncology Products" for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Get Access to FDA Approved Drugs / Anti-Cancer Medicines
For Lung Cancer Treatment in India

A cancer that begins in the lungs and most often occurs in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins and family history. Symptoms include a cough (often with blood), chest pain, wheezing and weight loss. These symptoms often don't appear until the cancer is advanced. Treatment depends on stage- Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy and immunotherapy.

The following lists anti-cancer drugs, US FDA and Indian Generic brand approved by the Food and Drug Administration (FDA) for Lung Cancer treatment. The list includes generic and brand names are in some way related to, or used in the treatment of this condition. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

LUMAKRAS

LUMAKRAS (sotorasib) tablets, for oral use Initial U.S. Approval: 2021

More Details...
ALECENSA

ALECENSA ® (alectinib) capsules, for oral use Initial U.S. Approval: 2015

More Details...
ALIMTA

ALIMTA (pemetrexed disodium) Injection, For Solution for Intravenous Use Initial U.S. Approval: 2004

More Details...
ALUNBRIG

ALUNBRIG (BRIGATINIB) film-coated tablets, for oral use Initial

More Details...
GILOTRIF

GILOTRIF ® (afatinib) tablets, for oral use Initial U.S. Approval: 2013

More Details...
HYCAMTIN

HYCAMTIN ® (topotecan hydrochloride) For Injection For Intravenous Use

More Details...
IMFINZI

IMFINZI ™ (durvalumab) injection, for intravenous use Initial U.S. Approval: 2017

More Details...
MEKINIST

MEKINIST (trametinib) tablets, for oral use Initial U.S. Approval: 2013

More Details...
OFEV

OFEV ® (nintedanib) capsules, for oral use Initial U.S. Approval: 2014

More Details...
PORTRAZZA

PORTRAZZA (necitumumab) injection, for intravenous use Initial U.S. Approval: 2015

More Details...
ROZLYTREK

ROZLYTREK (entrectinib) capsules, for oral use Initial U.S. Approval: 2019

More Details...
TABRECTA

TABRECTA (capmatinib) tablets, for oral use Initial U.S. Approval: 2020

More Details...
TARCEVA

TARCEVA ® (erlotinib) tablets, oral Initial U.S. Approval: 2004

More Details...
VARGATEF

VARGATEF (NINTEDANIB) 100 mg soft capsules, for oral use

More Details...
VIZIMPRO

VIZIMPRO ® (dacomitinib) tablets, for oral use Initial U.S. Approval: 2018

More Details...
AVASTIN

AVASTIN (bevacizumab) injection, for intravenous use Initial U.S. Approval: 2004

More Details...
CYENDIV

CYENDIV (nintedanib) capsules, for oral use Initial U.S. Approval: 2014

More Details...
CRIZALK

CRIZALK (crizotinib) Capsules, oral Initial U.S. Approval: August 2011

More Details...
ERLONAT

ERLONAT (erlotinib) tablets, oral Initial U.S. Approval: 2004)

More Details...
GEFTINAT

GEFTINAT (gefitinib) tablets for oral use Initial U.S. Approval: 2015

More Details...
GEMCITABINE

Gemcitabine for injection Powder, Lyophilized, For Solution For Intravenous Use

More Details...
NINTENA

NINTENA (nintedanib) capsules, for oral use Initial U.S. Approval: 2014

More Details...
PEMNAT

PEMNAT (paclitaxel protein-bound particles for injectable suspension), for intravenous use Initial U.S. Approval: 2005

More Details...
TAGRISSO

TAGRISSO ™ (osimertinib) tablet, for oral use Initial U.S. Approval: 2015

More Details...
TECENTRIQ

TECENTRIQ ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016

More Details...

Your Query Form

Head Office

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi, New Delhi:110016 India.

Mobile / WhatsApp Number:
Mobile: +91-9891296838 / 9811747774
WhatsApp: +91-9891296838 / 9811747774

Contact Details:
Phone: +91-11-26532129 / 26536398
Fax: +91-11-26532129 / 26536398

E Mail:
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Social Media:
Note:-

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Indian Pharma Network is registered medical pharmacy for Oncology Products in India.Helps you to access FDA approved Lung Cancer medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery. We have helped more than 6,000 patients. Send your enquiry to find the What is the cost of Lung Cancer Medicines in China, UAE, Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

If you have a question relating to anti-cancer medicines approved for treatment of Lung Cancer, a problem which you do not know how to resolve it, or concrete inquiry - we are here for you. We will answer you via email urgent@indianpharmanetwork.co.in as soon as possible. If you prefer to be contacted by phone, please leave your phone number. Or text your message in WhatsApp Number +91 9891296838 / 9811747774.

Indian Pharma Network, New Delhi. India

IPN, Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals.
Specialized in Oncology and other pharma products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Mumbai | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur | Punjab | Chandigarh
Our Overseas Network Uk | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa